Role of the tissue factor pathway in the pathogenesis and management of multiple organ failure

Blood Coagulation and Fibrinolysis

Volumn 15, Issue SUPPL. 1, 2004, Pages

  Smithies, Mark N ^a,b   Weaver, Christine B ^a  

^a CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Intensive care; Multiple organ failure; Sepsis; Tissue factor

Indexed keywords

ANTIINFECTIVE AGENT; APC; CORTICOSTEROID; DROTRECOGIN; GLUCOSE; HEPARIN; PLACEBO; RECOMBINANT ANTITHROMBIN III; RECOMBINANT THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL THERAPY; CLINICAL FEATURE; CONFERENCE PAPER; CORTICOSTEROID THERAPY; DIABETES CONTROL; DISEASE SEVERITY; DRUG MEGADOSE; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; FIBRINOLYSIS; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INFLAMMATORY INFILTRATE; INSULIN RESISTANCE; LOW DRUG DOSE; MULTIPLE ORGAN FAILURE; OUTCOMES RESEARCH; PATHOGENESIS; PATHOPHYSIOLOGY; POINT MUTATION; PRIORITY JOURNAL; REGULATORY MECHANISM; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SURVIVAL TIME; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOSIS; TISSUE OXYGENATION; UPREGULATION;

EID: 2942557303     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200405001-00003     Document Type: Conference Paper

References (54)

1. Bochud P-Y, Calandra T. Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 2003; 326:262-266.
2. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655.
3. Hoyert DL, Arias E, Smith BL, Murphy SL, Kochanek KD. Deaths: final data for 1999. Natl Vital Stat Rep 2001; 49:1-113.
4. Angus DC, Minde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310.
5. Intensive Care National Audit and Research Centre. Case Mix Programme Database; 2001. http://www.icnare.org/Cmp.htm.
6. MacKirdy F, Harris G, Mackenzie SJ. The epidemiology of sepsis in Scottish Intensive Care units [Abstract]. Critical Care 2003; 7:P027.
7. Davies A, Green C, Chinn C, Hutton J. Severe sepsis and septic shock: a European estimate of the cost of illness in ICUs. Presented at the European Society of Intensive Care Medicine 14th Annual Congress, Geneva, Switzerland, 30 September-3 October 2001.
8. Balk RA. Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock. Crit Care Clin 2000; 16:337-352.
9. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time? Crit Care Med 1998; 26:2078-2086.
10. Opal SM, Cohen J. Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis? Crit Care Med 1999; 27:1608-1616.
11. Linde-Zwirble WT, Angus DC, Carcilio J, et al. Age-specific incidence and outcome of sepsis in the US [Abstract]. Crit Care Med 1999; 27:A33.
12. Esmon CT. Inflammation and thrombosis: mutual regulation by protein C. Immunologist 1998; 6:84-89.
13. Lopes-Bezerra LM, Filler SG. Endothelial cells, tissue factor and infectious diseases. Braz J Med Biol Res 2003; 36:987-991.
14. Mészâros K, Aberle S, Dedrick R, Machovich R, Horwitz A, Birr C, et al. Monocyte tissue factor induction by lipopolysaccharide (LPS): dependence on LPS-binding protein and CD14, and inhibition by a recombinant fragment of bactericidal/permeability-increasing protein. Blood 1994; 83:2516-2525.
15. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000; 28(9 suppl): S31-S33.
16. Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998; 24:33-44.
17. Fourrier F, Chopin C, Goudemand J, Hendryex S, Caron C, Rime A, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101:816-823.
18. Kidokoro A, Iba T, Hong J. Role of DIC in multiple organ failure. J Surg Investig 2000; 2:73-80.
19. Evans TW, Smithies M. ABC of intensive care: organ dysfunction. BMJ 1999; 318:1606-1609.
20. Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, et al. Risk and efficacy of anti-inflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166:1197-1205.
21. Natanson C, Esposito CJ, Banks SM. The sirens' songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 1998; 26(12):1927-1931.
22. Bakhshi S, Arya LS. Diagnosis and treatment of disseminated intravascular coagulation. Indian Pediatr 2003; 40:721-730.
23. Nimah M, Brilli RJ. Coagulation dysfunction in sepsis and multiple organ system failure. Crit Care Clin 2003; 19:441-458.
24. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13:516-530.
25. Esmon CT. Regulation of blood coagulation. Biochem Biophys Acta 2000; 1477:349-360.
26. Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Hemost 1991; 66:6-15.
27. Dickneite G, Paques EP. Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumonia-induced sepsis. Thromb Haemost 1993; 69:98-102.
28. Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998; 24:663-672.
29. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79:918-925.
30. Lyseng-Williamson KA, Perry CM. Drotrecogin alfa (activated). Drugs 2002; 62:617-632.
31. Opal SM, Palardy J E, Parejo NA, Creasey AA. The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis. Crit Care Med 2001; 29:13-17.
32. de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95:1124-1129.
33. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
34. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286:1869-1878.
35. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290:238-247.
36. Angus DC, Laterre P-F, Helterbrand J, Ball D, Garg R, Bernard GR. The effects of drotrecogin alfa (activated) on long-term survival after severe sepsis. Presented at the Chest Annual Meeting, 2-7 November 2002, San Diego, California, USA.
37. Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003; 31:1-11.
38. Grey ST, Tsuchida A, Hau H, Orthner CL, Salem HH, Hancock WW. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol 1994; 153:3664-3672.
39. Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29:2081-2089.
40. Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, et al. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 2003; 102:3085-3092.
41. Aird WC. The hematologic system as a marker of organ dysfunction in sepsis. Mayo Clin Proc 2003; 78:869-881.
42. Torres A, Serra-Batlles J, Ros E, Piera C, Puig de la Bellacasa J, Cobos A, et al. Pulmonary aspiration of gastric contents in patients receiving mechanical ventilation: the effect of body position. Ann Intern Med 1992; 116:540-543.
43. Kollef MH. The prevention of ventilator-associated pneumonia. N Engl J Med 1999; 340:627-634.
44. O'Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51:1-29.
45. Boyce JM, Pittet D. Guidelines for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. MMWR Recomm Rep 2002; 51:1-45.
46. Lam NP, Le PD, Crawford SY, Patel S. National survey of stress ulcer prophylaxis. Crit Care Med 1999; 27:98-103.
47. Lowy FD. Staphylococcus aureus infections. N Engl J Med 2003; 339:520-532.
48. Heiselman D, Jones J, Cannon L. Continuous monitoring of mixed venous oxygen saturation in septic shock. J Clin Monit 1986; 2:237-245.
49. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377.
50. Hickling KG, Walsh J, Henderson S, Jackson R. Low mortality rate in adult respiratory distress syndrome using low-volume, pressure-limited ventilation with permissive hypercapnia: a prospective study. Crit Care Med 1994; 22:1568-1578.
51. Dries DJ. Weaning from mechanical ventilation. J Trauma 1997; 43:372-384.
52. Suter PM, Sedation during weaning from mechanical ventilation. Clin Intensive Care 1994; 5(suppl):8-12.
53. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-1367.
54. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871.